42365-68-4

Usage

Uses

Used in Pharmaceutical Industry:
3-HYDROXY-4-METHOXYBENZYLAMINE HYDROCHLORIDE is used as a pharmaceutical intermediate for the synthesis of various drugs due to its unique chemical properties and potential therapeutic effects.
Used in Neurological Applications:
3-HYDROXY-4-METHOXYBENZYLAMINE HYDROCHLORIDE is used as a selective and reversible inhibitor of monoamine oxidase (MAO) for the treatment of conditions such as depression, anxiety, and neurodegenerative diseases. It modulates neurotransmitter levels in the brain, providing potential therapeutic benefits.
Used in Anti-Aging and Anti-Cancer Therapies:
3-HYDROXY-4-METHOXYBENZYLAMINE HYDROCHLORIDE is used as a potential therapeutic agent in anti-aging and anti-cancer therapies due to its ability to reduce oxidative stress and inflammation, which are implicated in the aging process and the development of cancer.

InChI:InChI=1/C8H11NO2/c1-11-8-3-2-6(5-9)4-7(8)10/h2-4,10H,5,9H2,1H3

Upstream product

• 621-59-0 isovanillin 
• 222533-31-5 methanesulfonic acid 5-(acetylamino-methyl)-2-methoxy-phenyl ester 
• 98910-57-7 2-methoxyphenyl mesylate 
• 222533-34-8 N-(3-hydroxy-4-methoxy-benzyl)-acetamide 

Downstream Products

• 943347-54-4 (4Z)-5-bromo-4-{[(3-hydroxy-4-methoxybenzyl)amino]methylene}isoquinoline-1,3(2H,4H)-dione 
• 1620085-95-1 6-amino-7-(1H-benzo[d]imidazol-2-yl)-5-(3-hydroxy-4-methoxybenzyl)-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitrile 
• 161832-13-9 tert-butyl 3-hydroxy-4-methoxybenzylcarbamate 

Relevant academic research and scientific papers

Reusable Nickel Nanoparticles-Catalyzed Reductive Amination for Selective Synthesis of Primary Amines

The preparation of nickel nanoparticles as efficient reductive amination catalysts by pyrolysis of in situ generated Ni-tartaric acid complex on silica is presented. The resulting stable and reusable Ni-nanocatalyst enables the synthesis of functionalized and structurally diverse primary benzylic, heterocyclic and aliphatic amines starting from inexpensive and readily available carbonyl compounds and ammonia in presence of molecular hydrogen. Applying this Ni-based amination protocol, -NH2 moiety can be introduced in structurally complex compounds, for example, steroid derivatives and pharmaceuticals.

Efficient hydrogenation of benzaldoximes and Schiff bases on ceramic high-porosity palladium catalysts

An efficient catalytic method for the synthesis of benzyl- and dibenzylamines by hydrogenating oximes and Schiffbases was developed on palladium supported high-porosity foamed ceramic block catalyst. The multiple regeneration ability of the foamed ceramic block catalyst can significantly decrease the Pd consumption as compared to the use of the conventional 10%Pd/C catalyst. Owing to a high hardness of the foamed ceramic catalyst, the reaction mixture can rapidly be removed from the reactor without using filtering devices. The structures produced by the reaction are fragments of biologically active and natural molecules. Antiproliferative properties of dibenzylamines revealed on the sea urchin embryo model suggest that these compounds can be considered as promising agents for the design of new anticancer drugs.

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4

The series of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-dione and 4-[(pyridylmethyl)aminometh-ylene]isoquinoline-1,3-(2H,4H)-dione derivatives reported here represents a novel class of potential antitumor agents, which potently and selectively inhibit CDK4 over CDK2 and CDK1. In the benzylamino headpiece, a 3-OH substituent is required on the phenyl ring for CDK4 inhibitory activity, which is further enhanced when an iodo, aryl, heteroaryl, t-butyl, or cyclopentyl substituent is introduced at the C-6 position of the isoquinoline-1,3-dione core. To circumvent the metabolic liability associated with the phenolic OH group on the 4-substituted 3-OH phenyl headpiece, we take two approaches: first, introduce a nitrogen o- or p- to the 3-OH group in the phenyl ring; second, replace the phenyl headpiece with N-substituted 2-pyridones. We present here the synthesis, SAR data, metabolic stability data, and a CDK4 mimic model that explains the binding, potency, and selectivity of our CDK4 selective inhibitors.

Mesyl guaiacol: A versatile intermediate for the synthesis of 5-aminomethyl guaiacol and related compounds

An original synthetic pathway for the preparation of 5-substituted guaiacol derivatives is described. This method relies on the deactivation of the phenol group by converting it into the corresponding mesyl ester. Amidomethylation reactions lead to regioselective C-C bond formation at the 5-position of guaiacol. Thus, 5-aminomethyl-guaiacol was obtained in four steps and 75% overall yield.